JOHN KIRKWOOD to Drug Evaluation
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Drug Evaluation.
Connection Strength
0.233
-
Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer. 2004 Aug; 40(12):1825-36.
Score: 0.055
-
In vivo drug sensitivity assay of clonogenic human melanoma cells and correlation with treatment outcome. Cancer Res. 1983 Jul; 43(7):3434-40.
Score: 0.051
-
Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial. Cancer Res. 1992 Feb 15; 52(4):851-6.
Score: 0.023
-
Role of interferons in the therapy of melanoma. J Invest Dermatol. 1990 Dec; 95(6 Suppl):180S-184S.
Score: 0.021
-
A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 1990 Oct; 8(10):1637-49.
Score: 0.021
-
A randomized phase I/II study of continuous versus intermittent intravenous interferon gamma in patients with metastatic melanoma. J Clin Oncol. 1987 Nov; 5(11):1804-10.
Score: 0.017
-
Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. Ann Intern Med. 1985 Jul; 103(1):32-6.
Score: 0.015
-
Interferons in the treatment of human cancer. J Clin Oncol. 1984 Apr; 2(4):336-52.
Score: 0.013
-
Phase II trial of mitolactol in patients with metastatic melanoma. Cancer Treat Rep. 1982 Jan; 66(1):195-6.
Score: 0.011
-
Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1991 Oct; 9(10):1806-10.
Score: 0.006